Singular will work with Osteopore to validate an AI-based model for cranial implant design that was developed by the CSIRO.

Singular Health Group’s (ASX:SHG) testing of the model has achieved segmentation of the cranium and generation of cranial implant in less than four minutes with 91% accuracy.

It will now work with Osteopore (ASX:OSX) to validate the model by comparing the AI model and 3Dicom Surgical workflow to existing workflows and evaluated based on relative time and accuracy of the model.

This work seeks to collate empirical data to develop a pathway to full FDA approval for the AI model and deployment for use with Osteopore’s cutting-edge bioresorbable material. The company will also seek Australian TGA certification.

“I have to highly commend the innovative development and work ethic of the CSIRO team,” chief executive officer Thomas Hanly said.

“This best-in-class model, compared to the 2021 AutoImplant Grand Challenge, really demonstrates the ability of AI to accelerate the manual processes in the Scan to Surgery workflow.”

Ostepore CEO Khoon Seng Goh added that following a review of the new AI-driven cranial implant design tool and 3Dicom Surgical, his company was excited to begin the collaboration and to work towards a commercial outcome.

Cranial Implant

Singular Health Group
Source: Singular Health

The Cranial Implant Design project was started by CSIRO in October 2021 under its Kick-Start initiative that provides funding and support for innovative Australian start-ups and small businesses to access CSIRO’s research expertise and capabilities.

Singular Health’s internal development team have now configured the model to use standard DICOM inputs to work across both Windows and MacOS hardware, and to output the generated cranial implant design into the Company’s 3Dicom Surgical software.

Whilst in 3Dicom Surgical, the cranial implant can be edited in either the 2D or 3D views by a surgeon or bioengineer to make patient specific edits and increase the accuracy to near 100%.




This article was developed in collaboration with Singular Health Group, a Stockhead advertiser at the time of publishing.


This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.